"Designing Growth Strategies is in our DNA"
In February 2016, Exelixis, Inc. and Ipsen Pharma announced the licencing agreement to develop and commercialise cabozantinib, a drug indicated to treat medullary thyroid cancer. Medullary thyroid cancer is a rarer form of thyroid cancer or thyroid carcinoma, originating from the parafollicular cells or C cells (a form of neuroendocrine cells), which aid in the production of the hormone calcitonin.
Medullary thyroid cancer first generally originates as a nodule on the thyroid, which is further evaluated to determine if it is benign or cancerous. If the node is found to be cancerous, then it can be further classified into four types of thyroid cancer: medullary, papillary, Hurthle or follicular cancer.
To gain extensive insights into the market, Request for Customization
Initially, there are no symptoms of medullary thyroid cancer, unless an unusual lump in the neck/throat has been noticed by the patient or someone else and in some instances, the lump is painful to touch. Treatment for medullary thyroid cancer include surgical procedures, thyroidectomy, radiation therapy, systemic therapy, medications and chemotherapy.
The global medullary thyroid cancer treatment market growth is expected to driven by number of factors such as increased prevalence of thyroid cancers, increasing advancements in treatment of medullary thyroid cancers, good prognosis rates in early detection, increasing demand for preventive care leading to early diagnosis and increasing awareness.
According to the American Thyroid Association (ATA), medullary thyroid cancer accounts for 1%-2% of all total thyroid cancers. The American Cancer Society (ACS) estimates that sporadic medullary thyroid cancer occurs in 8 out of 10 diagnoses and is more prevalent in the aging populace than the familial form of medullary thyroid cancer, which has a favorable prognostic outcome.
The factors expected to limit the growth of the global medullary thyroid cancer treatment market includes the associated side effects of treatment, lack of early diagnosis and complications associated with surgeries
Some of the major companies that are present in the global medullary thyroid cancer treatment market are AstraZeneca, Millennium Pharmaceuticals, Inc., Sanofi, Eli Lilly and Company, Exelixis, Inc and other prominent players.
By Treatment Type
· Tyrosine kinases receptors inhibitors
· Other cytotoxic agents
By Distribution Channel
· Hospital pharmacy
· Retail pharmacy
· Online pharmacy
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
At present, chemotherapy is anticipated to dominate the treatment type segment in the global medullary thyroid cancer treatment market as therapeutics are the first line of treatment of the disease indication.
The global medullary thyroid cancer treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is estimated to dominate the global medullary thyroid cancer treatment market due to a number of factors such as the increasing prevalence of thyroid cancer, increasing research & development, established healthcare system, high medical expenditure and presence of key players. Asia Pacific is the fastest emerging market due to increasing incidences of thyroid cancers, increasing adoption of advanced treatment, increasing awareness of diseases, developing healthcare system and large population pools.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry